Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JW0104 + C2402 is an investigational **oral fixed-dose combination therapy** being developed for the treatment of **hypertension and dyslipidemia**. The combination consists of JW0104, a small molecule with clinical activity against cardiovascular and metabolic diseases, and C2402, a distinct compound whose pharmacological profile is being evaluated in tandem with JW0104[1][2][3][4][9][10]. Phase 1 studies have focused on safety and pharmacokinetics in healthy volunteers, and Phase 3 studies are underway (not yet recruiting, as of September 2025) to compare JW0104 + C2402 directly with other combinations and monotherapy in patients. The primary indication is the **joint management of high blood pressure (hypertension) and abnormal blood lipid levels (dyslipidemia)**. JW Pharmaceutical is leading development; mechanism of action details for the individual components are not publicly disclosed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JW0104 + C2402.